Every year, more than 3,000 scientific abstracts are accepted for oral and poster presentation at the Society's annual meeting.
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research
Hear top experts in hematologic malignancies discuss the latest developments in clinical care.
Thoughtful commentaries on several of the most meaningful hematologic breakthroughs of 2014, written by editors of The Hematologist and selected guest experts.
Obtain CME credit and a certificate of attendance for the 56th ASH Annual Meeting by April 17, 2015.
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to medical research.
Search a database of practicing hematologists in your area.
Help move hematology forward by supporting research, career development, and quality care and education programs.
Become part of a global network of more than 16,000 hematologists working to conquer blood diseases.
This morning the Honorable Barbara Mikulski (D-Md), a strong advocate for biomedical research funding, announced that she will retire from Congress at the end of her term in 2016.
This week the American Board of Internal Medicine (ABIM) announced needed changes to its Maintenance of Certification (MOC) program, specifically placing a temporary suspension on the Practice Assessment requirement and freezing MOC enrollment fees through 2017.
Amid the growing debate about the high price of powerful new drugs in the United States, a recent analysis suggests that breakthrough therapies for blood cancers may, in many cases and with some important caveats, provide reasonable value for money spent. Researchers present this viewpoint, based upon a comprehensive analysis of published cost-effectiveness ratios, online today in Blood, the Journal of the American Society of Hematology (ASH).
Today the White House unveiled a proposed Fiscal Year 2016 budget asking Congress to approve approximately $31.3 billion in funding for the National Institutes of Health (NIH).
On February 12, 2015, the Center for Medicare and Medicaid Innovation (CMMI) revealed the opportunity for practices to participate in a payment model dedicated the care of patients with cancer. Although there will be additional details to finalize, CMMI would like practices to express interest in participating in the model by April 23, 2015, even though it will not begin paying with this method until 2016. Click on the headline to read more.
On January 30, ASH submitted comments on the Food and Drug Administration's (FDA)
on Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs). The Guidance Document proposes that FDA assert its regulatory authority and increase oversight of LDTs. Click on the link above to read more about ASH's comments.
On January 28, The American Society of Hematology (ASH) submitted
on the National Institutes of Health's (NIH) Draft Policy to promote the use of a single Institutional Review Board (IRB) of record for domestic sites of multi-site clinical studies funded by NIH. The draft NIH policy proposes that all NIH-funded, multi-site studies carried out in the United States, whether supported through grants, contracts, or the NIH intramural program, should use a single IRB. Read more to learn about ASH's stance on the policy.
The Oncologic Drugs
Advisory Committee (ODAC) of the Food and Drug Administration (FDA) recommended
the approval of the first application for a biosimilar drug on January 7. The panel recommended that FDA approve the
application for a biologic agent similar to filgrastim. This drug would be used for a number of
applications in hematology.
For more than a century, clinicians have recognized myeloproliferative neoplasms (MPNs) as disorders that are characterized by expansion of different myeloid lineages, with important clinical sequelae. However, the seminal insight into these diseases came when Dr. William Dameshek wrote in an editorial in Blood that MPNs share specific clinical features including thrombosis, bleeding, and an increased risk of progression to leukemia.
Tamunomieibi Wakama, MD, is a visiting physician at Roswell Park Cancer Institute (RPCI) thanks to a Visitor Training Program (VTP) grant from ASH that was awarded to Vishala Neppalli, MD, assistant professor of oncology in the Department of Pathology & Laboratory Medicine at RPCI.
As we opened the first three clinical trials of JAK inhibitors in the summer of 2007 at MD Anderson Cancer Center, there was palpable enthusiasm and much anticipation among both physicians and patients. I vividly remember my first patient who enrolled in the phase I/II trial of ruxolitinib (the very first person in the world to be treated with a JAK inhibitor, in fact). He was an older man with massive splenomegaly and hepatomegaly resulting is ascites and swelling of the legs, severely compromising his ambulation and quality of life.
New Drugs to Match My New Genes? A Look Back at the 56th ASH Annual Meeting
For us hematologists, the first full weekend in December is typically blacked out in our calendars. During this sacred time, ASH hosts its annual meeting for anyone interested in the basic science, clinical
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology